Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2022 | AOCs: future outlooks in other disease areas

Arthur Levin, PhD, Avidity Biosciences, La Jolla, CA, briefly discusses the future of antibody-oligonucleotide conjugates (AOCs) for the treatment of neuromuscular disorders, commenting on the possibility of targeting several different cell surface receptors and using a variety of monoclonal antibodies (mAbs) to deliver therapeutic agents and treat a wide range of diseases. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.


Dr Levin is an employee of Avidity Biosciences, a Board member at Stoke Therapeutics, and a SAB member at Atalanta Therapeutics.